THX Pharma and Biocodex Forge €173 Million Licensing Deal for Rare Neurological Disease Treatments
核心洞察
THX Pharma (搜索) and Biocodex have signed a strategic licensing agreement worth up to €173 million to develop treatments for three rare neurological diseases: Batten disease (搜索), Gaucher disease (搜索), and Niemann-Pick disease type C (搜索).
Biocodex acquired exclusive global rights to Batten-1, a drug candidate preparing for Phase 3 trials in 2026 for juvenile Batten disease (搜索), which currently has no approved treatments.
The deal includes a €12 million upfront payment, up to €161 million in milestone payments, and tiered double-digit royalties, with THX Pharma (搜索) leading clinical development while Biocodex handles commercialization.
THX Pharma (搜索) and Biocodex have announced a major strategic licensing agreement valued at up to €173 million to advance treatments for three rare neurological diseases with significant unmet medical needs. The deal covers Batten-1 for juvenile Batten disease (搜索) and TX01 for Gaucher disease (搜索) and Niemann-Pick disease type C (搜索), conditions that predominantly affect pediatric populations and cause severe progressive impairments.
Deal Structure and Financial Terms
Under the agreement, Biocodex will receive two distinct licenses from THX Pharma (搜索). The company acquired exclusive global rights to develop and commercialize Batten-1, while securing regional exclusive rights covering the United States and Canada for TX01. THX Pharma will receive a €12 million upfront payment, with potential additional payments of up to €161 million in development and commercialization milestones, plus tiered double-digit royalties on net sales.
The collaboration structure designates THX Pharma (搜索) as the lead for clinical development programs, supported financially and scientifically by Biocodex. Biocodex will handle compassionate use programs, market access initiatives, and commercialization activities within their licensed territories.
Batten-1: Targeting an Ultra-Rare Pediatric Condition
Batten-1 represents a potentially groundbreaking development for juvenile Batten disease (搜索) (CLN3 (搜索)), an ultra-rare pediatric neurodegenerative disorder. The condition causes progressive loss of vision, cognitive and motor functions, ultimately leading to death in early adulthood. Currently, no treatment has been approved for this devastating condition.
The drug candidate is preparing for a Phase 3 clinical trial with initiation planned for 2026. If successful, Batten-1 aims to become the first available therapy for juvenile Batten disease (搜索), with an international launch targeted around 2030. THX Pharma (搜索) will lead the Phase 3 study with scientific and financial support from Biocodex, while Biocodex will manage marketing authorizations, market access, and commercialization.
TX01: Reformulated Approach for Lysosomal Diseases
TX01 takes a novel approach by utilizing an adapted oral formulation of an already approved active ingredient to treat two rare lysosomal diseases. For Niemann-Pick disease type C (搜索), a severe neurodegenerative disorder causing progressive decline in motor and cognitive functions with reduced life expectancy, TX01 offers potential therapeutic benefits. The formulation also targets Gaucher disease (搜索) type 1, a rare metabolic disorder characterized by lipid accumulation in organs that can lead to hematological, skeletal, and visceral complications.
This reformulation strategy aims to improve treatment administration and better address the specific needs of patients with these conditions.
Strategic Alignment and Company Perspectives
The partnership aligns with Biocodex's longstanding commitment to rare neurological diseases, building on over thirty years of expertise in the field. The company's approach combines scientific rigor with long-term clinical development and a focus on the complete patient and family journey beyond treatment alone.
Mathieu Charvériat, President and Chief Executive Officer of THX Pharma (搜索), emphasized the significance of the partnership: "This strategic agreement with Biocodex represents a major step forward and a significant value-creation milestone for THX Pharma. It validates the scientific and strategic value of our assets by partnering with a leading French pharmaceutical company with strong clinical development capabilities, recognized industrial and regulatory expertise, and a solid international commercial presence in the field of rare neurological diseases."
Nicolas Coudurier, Chief Executive Officer of Biocodex, highlighted the alignment with company strategy: "By partnering with THX Pharma (搜索), Biocodex is fully aligned with its innovation strategy dedicated to rare diseases with high unmet medical needs. Building on the experience gained with Diacomit® in Dravet syndrome (搜索), we were convinced by THX Pharma's scientific expertise and the strong alignment with our values of innovation in the service of health."
Addressing Critical Medical Needs
These genetically inherited diseases represent significant challenges in healthcare, often affecting pediatric populations and causing severe progressive visceral, hematological, or neurological impairments. The conditions have a major impact on patients' quality of life and life expectancy, with either no therapeutic options or very limited treatment alternatives available.
The collaboration extends beyond commercial interests, with both companies committed to ongoing dialogue with healthcare professionals and patient advocacy groups. Biocodex specifically mentioned their continued commitment alongside dedicated research organizations such as the Beyond Batten Disease Foundation.